Carmell Therapeutics Statistics Share Statistics Carmell Therapeutics has 30.12M
shares outstanding. The number of shares has increased by 46.44%
in one year.
Shares Outstanding 30.12M Shares Change (YoY) 46.44% Shares Change (QoQ) 44.08% Owned by Institutions (%) n/a Shares Floating 14.74M Failed to Deliver (FTD) Shares 1,923 FTD / Avg. Volume 0.02%
Short Selling Information Short Interest n/a Short % of Shares Out n/a Short % of Float n/a Short Ratio (days to cover) n/a
Valuation Ratios The PE ratio is -2.72 and the forward
PE ratio is null.
Carmell Therapeutics's PEG ratio is
-0.01.
PE Ratio -2.72 Forward PE n/a PS Ratio 0 Forward PS n/a PB Ratio 1.7 P/FCF Ratio -5.01 PEG Ratio -0.01
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Carmell Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 1.63,
with a Debt / Equity ratio of 0.09.
Current Ratio 1.63 Quick Ratio 1.63 Debt / Equity 0.09 Debt / EBITDA -0.14 Debt / FCF -0.25 Interest Coverage -5.87
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-1.72M Employee Count 9 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax -760.16K Effective Tax Rate 4.69%
Stock Price Statistics The stock price has increased by -90.05% in the
last 52 weeks. The beta is 0.51, so Carmell Therapeutics's
price volatility has been higher than the market average.
Beta 0.51 52-Week Price Change -90.05% 50-Day Moving Average 0.25 200-Day Moving Average 0.55 Relative Strength Index (RSI) 30.21 Average Volume (20 Days) 8,239,948
Income Statement
Revenue n/a Gross Profit -124.79K Operating Income -5.22M Net Income -15.45M EBITDA -15.19M EBIT -15.32M Earnings Per Share (EPS) -1.46
Full Income Statement Balance Sheet The company has 2.91M in cash and 2.14M in
debt, giving a net cash position of 776.01K.
Cash & Cash Equivalents 2.91M Total Debt 2.14M Net Cash 776.01K Retained Earnings -58.5M Total Assets 2.44M Working Capital -4.29M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -8.35M
and capital expenditures -30.47K, giving a free cash flow of -8.38M.
Operating Cash Flow -8.35M Capital Expenditures -30.47K Free Cash Flow -8.38M FCF Per Share -0.76
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
